



CORPORATE FACT SHEET

Corporate Overview

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases. The company's first approved product is APHEXDA™ (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. The company is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., BioLineRx is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.


*We are building a legacy of
changing lives around the world.*

R&D Programs

BioLineRx's focused pipeline includes novel compounds with best-in-class potential to meet areas of unmet need for patients with certain cancers and rare diseases.

PIPELINE TARGETING MULTIPLE INDICATIONS:

The safety and efficacy of the agents for the indications under investigation have not been established.



All trademarks are the property of their respective owners.

BioLineRx Management Team

Philip A. Serlin, CPA, MBA
Chief Executive Officer

Mali Zeevi, CPA
Chief Financial Officer

Ella Sorani, PhD
Chief Development Officer

Holly May, MBA
President, BioLineRx USA

Tsipi Keren-Lehrer, BSC, LLB
Head of BD and Strategic Advisor

Adam Janoff, Esq
General Counsel and Head of Compliance

For more information on BioLineRx's mission, programs and capabilities, visit www.biolinerx.com



Israel Headquarters

Modi'in Technology Park
2 HaMa'ayan Street
Modi'in 7177871, Israel
+972-8-642-9100

U.S. Operations

CityPoint
77 Fourth Avenue
Waltham, MA 02451 USA
+1-617-859-6409

Email: IR@BioLineRx.com

Web: <https://www.biolinerx.com>

LinkedIn: [@BioLineRx](https://www.linkedin.com/company/biolinerx)

Twitter: [@BioLineRx_Ltd](https://twitter.com/BioLineRx_Ltd)